



## Original Research Article

## To compare effects of pretreatment with two doses of dexmedetomidine on etomidate induced myoclonus and attenuation of stress response at intubation

Priyanka Gupta<sup>1</sup>, Santosh Kumari<sup>1</sup>, Renu Chauhan<sup>1</sup>, Parminder Singh Bhatia<sup>1,\*</sup>

<sup>1</sup>Dept. of Anesthesiology and Intensive Care, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India



## ARTICLE INFO

## Article history:

Received 28-03-2022

Accepted 15-05-2022

Available online 17-08-2022

## Keywords:

American Society of  
Anaesthesiologists (ASA)  
Diastolic Blood Pressure (DBP)  
Systolic Blood Pressure (SBP)  
Mean Arterial Pressure (MAP)  
Electrocardiogram (ECG)  
Heart Rate (HR)

## ABSTRACT

**Introduction:** Etomidate's haemodynamic stability is due to its unique lack of effect on the sympathetic nervous system and on baroreceptor function. Even in cardiac patients an induction dose of etomidate results in very stable haemodynamics. Etomidate also has minimal effects on respiratory system as compared to other induction agents. Since it causes minimal histamine release, this gives an advantage in patients with reactive airway disease, making it less likely that they will have bronchospasm. However, pain on injection and myoclonus are two most common side effects of this drug. Pain on injection has disappeared after the new fat emulsion of etomidate, but the new solvent has not reduced the incidence of myoclonus.

**Objectives:** 1): To compare the effects of pretreatment with two doses of Dexmedetomidine on the incidence of Etomidate induced myoclonus using numerical based grading; 2): To compare the effects of pretreatment with two doses of Dexmedetomidine on attenuation of stress response at laryngoscopy and intubation after induction with Etomidate.

**Materials and Methods:** Study area: The proposed study was carried out in the Department of Anesthesiology and Intensive care at a tertiary care teaching hospital, after seeking clearance from the college ethical committee and obtaining written informed consent from patient. Study design: Prospective Interventional Randomized Comparative Study Study period: 1 year

**Results:** It was a prospective and interventional randomized comparative study where 180 patients with age group 18-65 years, of either sex, ASA grade I & II, BMI, undergoing elective surgical procedures under general anaesthesia with endotracheal intubation were included in the study. They were divided into three groups where patients were randomly allocated into one of the three groups using Block Randomization with sealed envelope system. In Group 2 and 3, 78.3% and 76.6% patients did not have myoclonus during induction with etomidate. Stress response to intubation was suppressed by dexmedetomidine.

**Conclusion:** Based on the observations of our study, we conclude that pretreatment with 0.5 µg/kg and 1 µg/kg Dexmedetomidine significantly reduce etomidate induced myoclonus and stress response at intubation. However, dexmedetomidine in dose of 0.5 µg/kg is associated with fewer side effects of bradycardia and hypotension.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

### 1. Introduction

Etomidate is a carboxylatedimidazole-derived, sedative hypnotic agent. It acts directly on GABA Receptor

Complex, blocking neuroexcitation and producing anaesthesia. When introduced in 1973, it was considered a novel induction agent with a stable cardiovascular profile and minimal respiratory side effects and is still widely used for hemodynamically unstable patients.<sup>1</sup>

\* Corresponding author.

E-mail address: [psbhatia2@rediffmail.com](mailto:psbhatia2@rediffmail.com) (P. S. Bhatia).

Etomidate's haemodynamic stability is due to its unique lack of effect on the sympathetic nervous system and on baroreceptor function. Even in cardiac patients an induction dose of etomidate results in very stable haemodynamics. Etomidate also has minimal effects on respiratory system as compared to other induction agents. Since it causes minimal histamine release, this gives an advantage in patients with reactive airway disease, making it less likely that they will have bronchospasm. However, pain on injection and myoclonus are two most common side effects of this drug.<sup>2</sup> Pain on injection has disappeared after the new fat emulsion of etomidate, but the new solvent has not reduced the incidence of myoclonus.<sup>3</sup>

A variety of drugs have been used in the past to decrease the incidence of myoclonus like

1. Opioids- Fentanyl, Sufentanyl, Alfentanyl and Remifentanyl<sup>4-7</sup>
2. Benzodiazapines – Midazolam<sup>8-10</sup>
3. Magnesium Sulphate<sup>11</sup>
4. Alpha 2 agonists-Dexmedetomidine<sup>1,9,12</sup>

## 2. Objectives

1. To compare the effects of pretreatment with two doses of Dexmedetomidine on the incidence of Etomidate induced myoclonus using numerical based grading.
2. To compare the effects of pretreatment with two doses of Dexmedetomidine on attenuation of stress response at laryngoscopy and intubation after induction with Etomidate.

## 3. Materials and Methods

### 3.1. Study area

The proposed study was carried out in the Department of Anesthesiology and Intensive care at a tertiary care teaching hospital, after seeking clearance from the college ethical committee and obtaining written informed consent from patient.

### 3.2. Study design

Prospective Interventional Randomized Comparative Study

### 3.3. Study period

1 Year.

### 3.4. Inclusion criteria

Adult patients of 18-65 years of age of either sex of ASA grade 1 and 2 undergoing elective surgery under general anaesthesia were included in study.

### 3.5. Exclusion criteria

Patients with history suggesting allergy to any of the study medications, anticipated difficult airway, known Psychiatric disorder, sepsis/systemic infections, pacemaker/on Beta Blockers/with Heart Blocks and Pregnancy.

## 4. Results

The present study "To compare the effects of pretreatment with two doses of Dexmedetomidine on Etomidate induced myoclonus and attenuation of stress response at intubation" was conducted in the Operation Theatres in the Department of Anaesthesia and Intensive Care, at a tertiary care teaching hospital after obtaining clearance from ethical committee.

It was a prospective and interventional randomized comparative study where 180 patients with age group 18-65 years, of either sex, ASA grade I & II, BMI, undergoing elective surgical procedures under general anaesthesia with endotracheal intubation were included in the study. They were divided into three groups where patients were randomly allocated into one of the three groups using Block Randomization with sealed envelope system.

Group 1 (n=60): This group received 10 ml Saline followed by Inj. Etomidate (0.3 mg/Kg).

Group 2(n=60): This group received pretreatment with Inj. Dexmedetomidine (0.5µg/Kg) in 10ml Saline followed by Inj. Etomidate (0.3 mg/Kg).

Group 3 (n=60): This group received pretreatment with Inj. Dexmedetomidine (1µg/Kg) in 10ml Saline followed by Inj. Etomidate (0.3 mg/Kg).

The intensity of myoclonus was graded as follows

0-No myoclonus, 1- mild myoclonus, 2- moderate and 3-severe myoclonus.

In this study, there was no significant differences among three groups regarding age, weight, sex and ASA physical status.

In our study, incidence of myoclonus was maximum in Group 1(70%) while 47 out of 60 patients (78.3%) in Group 2 and 46 out of 60 patients (76.6%) in Group 3 had no myoclonus. It is shown in Table 2.

In our study, majority of patients in Group 1 had grade 2 myoclonus (31.67%), 30% had no myoclonus and 13.3% patients had grade 3 myoclonus compared to patients who were pretreated with dexmedetomidine. In Group 2 and 3 none of the patients had grade 3 myoclonus. Thus, showing the efficacy of dexmedetomidine in reducing incidence and severity of etomidate induced myoclonus as shown in Table 3.

Stress response to intubation was also attenuated in dexmedetomidine group. Both Heart rate and Systolic Bp were less post intubation in patients who were pretreated with injection dexmedetomidine compared to group 1 as shown in Figures 1 and 2.

**Table 1:** Comparison of age distribution between the groups


Age	Group			Total	P value
	1	2	3		
<=20	6 (10.00%)	3 (5.00%)	7 (11.67%)	16 (8.89%)	0.327
21-30	11 (18.33%)	18 (30.00%)	16 (26.67%)	45 (25.00%)	
31-40	17 (28.33%)	13 (21.67%)	16 (26.67%)	46 (25.56%)	
41-50	10 (16.67%)	17 (28.33%)	15 (25.00%)	42 (23.33%)	
51-60	15 (25.00%)	8 (13.33%)	6 (10.00%)	29 (16.11%)	
>60	1 (1.67%)	1 (1.67%)	0 (0.00%)	2 (1.11%)	
Total	60 (100.00%)	60 (100.00%)	60 (100.00%)	180 (100.00%)	

**Table 2:** Incidence of myoclonus

Myoclonus	Group			Total	P value
	1	2	3		
No	18(30.00%)	47(78.33%)	46(76.67%)	111(61.67%)	<0.0001
Yes	42(70.00%)	13(21.67%)	14(23.33%)	69(38.33%)	
Total	60(100.00%)	60(100.00%)	60(100.00%)	180(100.00%)	

**Table 3:** Distribution of myoclonus grade.

Grade of myoclonus	1	2	3	P value
0	18(30.00%)	47(78.33%)	46(76.67%)	<0.0001
1	10(16.67%)	9(15.00%)	11(18.33%)	
2	19(31.67%)	4(6.67%)	3(5.00%)	
3	13(21.67%)	0(0.00%)	0(0.00%)	
Total	60(100%)	60(100%)	60(100%)	



**Fig. 1:** HR Trend




Fig. 2: Systolic blood pressure trend

## 5. Discussion

In this prospective randomized clinical study, we compared the effects of pretreatment with two doses of dexmedetomidine on the incidence of etomidate induced myoclonus and attenuation of stress response at intubation. This study was conducted in 180 adult patients (18-65 years) of ASA I or II undergoing elective surgery under general anaesthesia. These patients were randomly allocated to three groups, with each group having 60 patients each. Several studies have reported incidence of myoclonus in 50-80% patients receiving etomidate.<sup>1,13,14</sup>

Doenicke et al showed higher doses of etomidate were correlated with increased frequency of myoclonus, which was 83% with 0.3mg/kg etomidate. None of the patients had myoclonus in doses under 0.005 mg/kg.<sup>13</sup>

Mizrak et al (2010) concluded that pretreatment with dexmedetomidine or thiopental is effective in reducing the incidence and severity of etomidate-induced myoclonic muscle movements. Incidence of myoclonus was significantly low in Dexmedetomidine (0.5µg/kg) and Thiopental (1mg/kg) groups (34%,36%) than in control groups (64%) (p<0.05).<sup>12</sup>

Gunes Y et al (2010) conducted a study in 152 patients to compare effect of midazolam and dexmedetomidine for prevention of etomidate induced myoclonus and pain. They randomly allocated the patients into 3 groups, pretreated either with saline, or midazolam 0.5mg/kg or dexmedetomidine 1µg/kg and concluded that both groups

pretreated with midazolam and dexmedetomidine showed significantly lower incidence of myoclonus as compared to group pretreated with saline. 37% patients in group pretreated with midazolam, 30% in group pretreated with dexmedetomidine and 90% in group pretreated with saline had myoclonus.<sup>15</sup>

Swarnendudey et al(2018) investigated effect of midazolam (0.015mg/kg) and dexmedetomidine (0.5µg/kg) in prevention of etomidate induced myoclonus in 80 adult patients. Incidence of myoclonus was much less in group receiving dexmedetomidine (45%) as compared to midazolam (52.5%). They also concluded that dexmedetomidine provides greater attenuation of stress response than midazolam.<sup>10</sup>

Sulaiman et al in 2012 studied the effects of dexmedetomidine on attenuation of stress response to endotracheal intubation. They concluded that dexmedetomidine provides good control of hemodynamics during laryngoscopy and endotracheal intubation. Dexmedetomidine at a dose of 0.5 mcg/kg as 10min infusion was administered prior to induction of general anaesthesia attenuated the sympathetic response to laryngoscopy and intubation in patients undergoing myocardial revascularization.<sup>16</sup>

Menda et al used dexmedetomidine in a dose of 1µg/Kg over 15 minutes before induction, to study its effects on attenuation of haemodynamic response to endotracheal intubation, found that the heart rate was significantly lower at all times as compared to the baseline values in the

intraoperative period.<sup>17</sup>

Scheinin et al (1992) concluded that dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and peroperative fentanyl.<sup>18</sup>

Koroglu et al. reported that a high dose of dexmedetomidine (bolus of 2-3 µg/kg over 10 min or infusion of 1.5-3 µg/kg/hr) in children undergoing MRI led to bradycardia in 16% of patients.<sup>19</sup>

H.F.Laun et al in their study reported incidence of bradycardia in group pretreated with dexmedetomidine 1 µg/kg was significantly higher than groups using saline and dexmedetomidine 0.5 µg/kg. In their study 24% patients in group III, 6.7% in group II, 0% in group I had bradycardia.<sup>1</sup>

## 6. Conclusions

1. Incidence and severity of etomidate induced myoclonus was significantly lesser in patients who received pretreatment with dexmedetomidine compared to patients who received saline.
2. Both the doses (0.5 µg/kg and 1 µg/kg) dexmedetomidine are equally effective in prevention of incidence and severity of myoclonus induced by etomidate.
3. Compared to patients who received saline, pretreatment with dexmedetomidine (0.5 µg/kg and 1 µg/kg) attenuates the stress response to laryngoscopy and intubation.
4. Both the doses (0.5 µg/kg and 1 µg/kg) dexmedetomidine are comparable in attenuation of stress response during laryngoscopy and intubation.
5. Side effects like bradycardia and hypotension were more with dexmedetomidine 1 µg/kg compared to 0.5 µg/kg dexmedetomidine.

## 7. Source of Funding

No financial support was received for the work within this manuscript.

## 8. Conflict of Interest

The authors declare they have no conflict of interest.

## References


1. Luan HF, Zhao ZB, Feng JY, Cui JZ, Zhang XB, Zhu P, et al. Prevention of etomidate induced myoclonus during anesthetic induction by pretreatment with dexmedetomidine. *Braz J Med Biol Res.* 2015;48(2):186–90. doi:10.1590/1414-431X20144100.
2. Doenicke A, Roizen MF, Nebauer AE, Kugler A, Hoerneck R, Beger-Hintzen H, et al. A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol. *Anesth Analg.* 1994;79(5):933–9. doi:10.1213/00000539-199411000-00020.
3. Bergen JM, Smith DC. A Review of Etomidate for rapid sequence intubation in the emergency department. *J Emerg Med.* 1997;15(2):221–30. doi:10.1016/s0736-4679(96)00350-2.
4. Stockham RJ, Stanley TH, Pace NL, Gillmor S, Groen F, Hilken P, et al. Fentanyl pretreatment modifies anaesthetic induction with etomidate. *Anaesth Intensive Care.* 1988;16(2):171–6. doi:10.1177/0310057X8801600207.
5. Heuter L, Schwarzkopf K, Simon M, Bredle D, Fritz H. Pretreatment with Sufentanyl reduces myoclonus after etomidate. *Acta Anaesthesiol Scand.* 2003;47(4):482–4. doi:10.1034/j.1399-6576.2003.00081.x.
6. Khalil SN, Lawson KS, Hanis CL, Lemak NA, Ruiz RS. Alfentanil decreases myoclonus caused by Etomidate. *Middle East J.* 1999;15:185–92.
7. Kelsaka E, Karakaya D, Sarihasan B, Baris S. Remifentanyl pretreatment reduces myoclonus After etomidate. *J Clin Anesth.* 2006;18(2):83–6. doi:10.1016/j.jclinane.2005.05.004.
8. Huter L, Schreiber T, Gugel M, Schwarzkopf K. Low-dose intravenous midazolam reduces etomidate-induced myoclonus: A prospective, randomized study in patients undergoing elective cardioversion. *Anesth Analg.* 2007;105(5):1298–302. doi:10.1213/01.ane.0000287248.25610.c0.
9. Schwarzkopf KR, Hueter L, Simon M, Fritz HG. Midazolam pretreatment reduces etomidate-induced myoclonic movements. *Anaesth Intensive Care.* 2003;31(1):18–20. doi:10.1177/0310057X0303100103.
10. Dey S, Kumar M. comparison of pretreatment with dexmedetomidine with midazolam for prevention of etomidate-induced myoclonus and attenuation of stress response at intubation: A randomized controlled study. *J Anaesthesiol Clin.* 2018;34(1):94–8. doi:10.4103/joacp.JOACP\_297\_16.
11. Guler A, Satilmis T, Akinci SB, Celebioglu B, Kanbak M. Magnesium sulfate pretreatment reduces myoclonus after etomidate. *Anesth Analg.* 2005;101(3):705–9. doi:10.1213/01.ANE.0000160529.95019.E6.
12. Mizrak A, Koruk S, Bilgi M, Kocamer B, Erkutlu I, Ganidagli S, et al. Pretreatment with Dexmedetomidine or thiopental decreases myoclonus after etomidate: a randomized, double-blind controlled trial. *J Surg Res.* 2010;159(1):e11–6. doi:10.1016/j.jss.2009.07.031.
13. Doenicke AW, Roizen MF, Kugler J, Kroll H, Foss J, Ostwald P, et al. Reducing Myoclonus after Etomidate. *Anesthesiology.* 1999;90:113–9. doi:10.1097/00005542-199901000-00017.
14. Ghoneim MM, Yamada T. Etomidate: a clinical and electroencephalographic comparison with thiopental. *Anesth Analg.* 1977;56(4):479–85. doi:10.1213/00000539-197707000-00003.
15. Gunes Y, Aktolga S, Gündüz M, Isik G. A comparison of midazolam or dexmedetomidine for the prevention of myoclonic movements and injection pain following etomidate injection. *J Int Med Res.* 2010;27(47):148.
16. Sulaiman SI, Karthekeyan RB, Vakamudi M, Sundar AS, Ravullapalli H. The effects of dexmedetomidine on attenuation of stress response to endotracheal intubation in patients undergoing elective off-pump coronary artery bypass grafting. *Ann Card Anaesth.* 2012;15(1):39–43. doi:10.4103/0971-9784.91480.
17. Menda F, Koner O, Sayin M, Ture H, Imer P, Aykac B, et al. Dexmedetomidine as an adjunct to anesthetic induction to attenuate hemodynamic response to endotracheal intubation in patients undergoing fast-track CABG. *Ann Card Anaesth.* 2012;13(1):16–21. doi:10.4103/0971-9784.58829.
18. Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M. Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and peroperative fentanyl. *Br J Anaesth.* 1992;68(2):126–31. doi:10.1093/bja/68.2.126.
19. Koroglu A, Demirbilek S, Teksan H, Sagir O, But AK, Ersoy MO, et al. Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: preliminary results. *Br J Anaesth.* 2005;94(6):821–4. doi:10.1093/bja/aei119.

## Author biography

**Priyanka Gupta**, Senior Resident  <https://orcid.org/0000-0001-7411-4535>

**Santosh Kumari**, Assistant Professor

**Renu Chauhan**, Assistant Professor

**Parminder Singh Bhatia**, Professor and Consultant  
 <https://orcid.org/0000-0002-6091-2568>

**Cite this article:** Gupta P, Kumari S, Chauhan R, Bhatia PS. To compare effects of pretreatment with two doses of dexmedetomidine on etomidate induced myoclonus and attenuation of stress response at intubation. *Panacea J Med Sci* 2022;12(2):436-441.